Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP520 multiple-dose study in healthy elderly subjects
NL-OMON42784Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing CNP520 with Placebo (2 arms). Primary endpoint: Safety and tolerability over 13 weeks. Started Jul 2015; status: active, not recruiting.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON42784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42784.